ACC cancer, short for adenoid cystic carcinoma, is a rare malignancy that develops in secretory glands, most often the salivary glands in the head and neck. It behaves differently from most cancers: it grows slowly, sometimes over years, but has an aggressive tendency to invade nearby nerves and eventually spread to distant organs. The five-year survival rate is about 74%, but that number drops to 49% at ten years and 27% at twenty years, reflecting the disease’s pattern of late recurrence long after initial treatment.
Where ACC Develops
The salivary glands are the most common starting point, including both the major glands (like the parotid gland near the ear) and the minor salivary glands scattered throughout the roof of the mouth, tongue, and throat. ACC can also arise in the lacrimal glands near the eyes, the lining of the nasal cavity, and the external ear canal.
Less commonly, ACC develops outside the head and neck entirely. Cases have been reported in the breast, windpipe, skin, and reproductive tract. Regardless of where it starts, the tumor tends to behave in similar ways: slow growth, a strong attraction to nerves, and a preference for spreading through the bloodstream rather than the lymph system. It most commonly affects women, with an average age at diagnosis of about 53.
Early Symptoms by Location
Because ACC grows slowly, early symptoms are often subtle and easy to dismiss. The most common first sign is a firm, painless lump in the mouth, jaw, or face when the tumor involves a salivary gland. Many people live with this mass for months before seeking evaluation, since it doesn’t always hurt.
When the tumor involves the lacrimal gland, it can cause a bulging eye or changes in vision. ACC in the windpipe or voice box may lead to breathing difficulty, hoarseness, or voice changes. As the tumor advances and begins invading nerves, pain, numbness, or tingling may develop. In some cases, nerve paralysis occurs, particularly with tumors near the parotid gland, which sits close to the facial nerve.
How ACC Spreads Along Nerves
The defining characteristic of ACC is its tendency to grow along nerve fibers, a behavior called perineural invasion. Tumor cells infiltrate the protective sheath surrounding nearby nerves and use them as a pathway to travel well beyond the visible tumor mass. This is sometimes described as a “fourth route” of cancer spread, distinct from the more familiar patterns of direct tissue invasion, blood-borne spread, or lymphatic spread.
This nerve-tracking behavior has serious clinical consequences. It makes it difficult for surgeons to determine where healthy tissue ends and cancerous tissue begins, since microscopic disease can extend far along a nerve. In one study, 80% of patients who had perineural invasion eventually experienced local or distant recurrence, even when surgical margins appeared clear. By contrast, only 27% of patients without nerve involvement had recurrence. Perineural invasion is also strongly linked to distant metastasis, making it one of the most important factors in predicting long-term outcomes.
Histological Subtypes and Prognosis
Under a microscope, ACC tumors fall into three growth patterns: cribriform, tubular, and solid. The cribriform pattern, which has a characteristic “Swiss cheese” appearance with small holes throughout the tissue, is the most common. The tubular pattern, featuring tube-like structures, generally carries a more favorable prognosis. The solid pattern, where tumor cells grow in dense sheets, is associated with worse outcomes.
A major meta-analysis of over 17,000 ACC patients identified the solid subtype as a significant predictor of poor survival, alongside advanced tumor size, positive lymph nodes, distant metastasis, and cancer left at surgical margins. A genetic hallmark of ACC is a specific chromosomal rearrangement that fuses two genes involved in cell growth regulation. This fusion is found in the majority of ACC tumors and is considered a defining molecular feature of the disease.
Distant Metastasis: The Lungs and Beyond
Unlike many head and neck cancers that spread first to nearby lymph nodes, ACC has a strong tendency to skip the lymphatic system and travel through the bloodstream to distant organs. An estimated 30 to 40% of ACC patients will develop distant metastasis within 10 to 15 years of their initial treatment, and these recurrences can appear remarkably late, sometimes a decade or more after the original tumor was removed.
The lungs are the most frequent target. Roughly 70% of patients with distant spread have lung involvement. Isolated lung metastases carry a somewhat better prognosis, with median survival of about four to four and a half years after detection. Bone metastases are more ominous, with median survival dropping to under two years. Distant metastasis is the most common adverse outcome in ACC overall, occurring on average about 35 months after diagnosis.
Surgery and Radiation as Primary Treatment
Surgical removal of the tumor is the preferred first-line treatment. The goal is complete resection with clear margins, though ACC’s nerve-tracking behavior makes this challenging. Surgeons often need to trace the involved nerve pathways well beyond the visible tumor to capture microscopic disease.
Radiation therapy after surgery is recommended in nearly all ACC cases because of the high risk of local recurrence. Specific situations that make post-surgical radiation especially important include incomplete tumor removal, margins that are positive or close, and the presence of perineural invasion. For tumors that cannot be surgically removed, radiation alone serves as the primary treatment, delivered at higher doses to the tumor and any nerves showing involvement on imaging.
Because ACC rarely spreads through the lymphatic system, radiation to the neck lymph nodes is not routine unless there is confirmed disease in those nodes or the tumor is particularly advanced. This is a notable difference from the treatment approach for many other head and neck cancers.
Why Chemotherapy Has Limited Effect
Traditional chemotherapy has proven largely disappointing for ACC. No standard chemotherapy regimen currently exists for the disease. When individual drugs have been tested, objective response rates have been low. In studies involving more than 160 patients treated with single-agent chemotherapy, only about 16% showed a measurable response. Some drugs showed virtually no activity at all.
Combination regimens perform somewhat better but still modestly. The most studied combinations produced response rates of 18 to 31%, with a platinum-based combination showing the highest rates. However, responses tend to be partial and temporary. Chemotherapy is generally reserved for advanced, unresectable, or metastatic disease when other options have been exhausted, and even then, the benefit is often limited to slowing progression rather than shrinking tumors significantly.
Drugs targeting blood vessel growth in tumors have been explored as alternatives, but their effectiveness has been comparable to conventional chemotherapy at best. The slow-growing nature of ACC, which gives it a relatively low rate of cell division, is thought to be one reason why chemotherapy drugs that target rapidly dividing cells are less effective.
Long-Term Outlook
ACC’s survival statistics tell an unusual story. The 74% five-year survival rate is relatively encouraging compared to many cancers, but the steady decline to 49% at ten years, 42% at fifteen years, and 27% at twenty years reveals the disease’s defining challenge: it keeps coming back. Many patients live for years or even decades with stable or slowly progressing metastatic disease, particularly when the spread is limited to the lungs.
The factors most strongly tied to worse outcomes are advanced tumor size at diagnosis, the solid histological subtype, perineural invasion, positive surgical margins, and the development of distant metastasis. Patients diagnosed with small, early-stage tumors that are completely removed and show no nerve involvement have substantially better long-term prospects. For this reason, long-term surveillance extending well beyond the standard five-year mark is essential, since recurrences can appear 10, 15, or even 20 years after treatment.